Troglitazone. Is it all over?

Netherlands Journal of Medicine

Volumn 55, Issue 1, 1999, Pages 4-12

  Wagenaar, L J ^a   Kuck, E M ^a   Hoekstra, J B L ^a  

^a DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Insulin resistance; Therapy; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE;

ARTICLE; DRUG CONTRAINDICATION; EUROPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; JAPAN; LIVER DYSFUNCTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ANIMALS; BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033002167     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00021-2     Document Type: Article

References (57)

1. Dagogo-Jack S., Santiago J.V. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 157:1997;1802-1817.
2. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
3. Anonymous. New warning information for Rezulin labeling. J Am Med Assoc 1997;278:1728.
4. Ufkes J.G.R. Glaxo Wellcome staakt verkoop veelbelovend antidiabeticum. Pharm Weekbl. 132:1997;1903-1904.
5. Henry R.R. Thiazolidinediones. Endocrinol Metab Clin North Am. 26:1997;553-573.
6. Kaneko T. Troglitazone (CS-045): a new antidiabetic agent. Horm Metab Res. 29:1997;203-213.
7. Yoshioka T., Fujita T., Kanai T., et al. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem. 32:1989;421-428.
8. Spencer C.M., Markham A. Troglitazone. Drugs. 54:1997;89-101.
9. Chaiken R.L., Eckert-Norton M., Pasmantier R., et al. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia. 38:1995;1307-1312.
10. Lebovitz H.E., Patel J., Dole J., Patwardhan R. Rosiglitazone (BRL49653) monotherapy has significant glucose effect in type 2 diabetic patients. Diabetologia. 41:(Suppl 1):1998;A238.
11. Saltiel A.R., Olefsky J.M. Perspectives in diabetes. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
12. Santiago J.V. Troglitazone. Compr Ther. 23:1997;560-562.
13. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 270:1995;12953-12956.
14. Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. N Engl J Med. 338:1998;908-909.
15. Petrie J., Small M., Conell J. 'Glitazones', a prospect for non-insulin-dependent diabetes. Lancet. 349:1997;70-71.
16. Whitcomb R.W., Saltiel A.R. Thiazolidinediones. Exp Opin Invest Drugs. 4:1995;1299-1309.
17. Nagasaka Y., Kaku K., Nakamura K., Kaneko T. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol. 50:1995;1109-1111.
18. Cominacini L., Young M.M.R., Capriati A., et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 40:1997;1211-1218.
19. Speerhas R.A., Reddy S.S.K. Troglitazone: a new antihyperglycemic agent. Cleve J Med. 64:1997;238-240.
20. Anonymous. New diabetes drug targets insulin resistance. Am J Health-Syst Pharm 1997;54:623-625.
21. Johnson M.D., Campbell L.K., Campbell R.K. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother. 32:1998;337-348.
22. Tanouye E. Warner issues warning over diabetes drug. Wall Street Journal (Midwest ed.). 100:(89):1997;A3-A6.
23. Antonucci T., Whitcomb R., McLain R., Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diab Care. 20:1997;188-193.
24. Berkowitz K., Peters R., Kjos S.L., et al. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes. 45:1996;1572-1579.
25. Cavaghan M.K., Ehrmann D.A., Byrne M.M., Polonsky K.S. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 100:1997;530-537.
26. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;3299-3306.
27. Ehrmann D.A., Schneider D.J., Sobel B.E., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
28. Foot E.A., Eastmond R. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects. Diab Res Clin Pract. 38:1997;41-51.
29. Ghazzi M.N., Perez J.E., Antonucci T.K., et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
30. Hansen A.P. Effects of troglitazone, a thiazolidinedione, in elderly non-insulin-dependent diabetic patients [abstract no. 775]. Diabetologia. 38:(Suppl. 1):1995;A200.
31. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338:1998;867-872.
32. Iwamoto Y., Kuzuya T., Matsuda A., et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diab Care. 14:1991;1083-1086.
33. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diab Care. 19:1996;151-156.
34. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diab Med. 13:1996;365-370.
35. Kumar S., Boulton A.J.M., Beck-Nielsen H., et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
36. Kuzuya T., Iwamoto Y., Kosaka K., et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diab Res Clin Pract. 11:1991;147-154.
37. Leutenegger M., Sacca L., Alderton C., Eckland D., Lettis S. Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus. Curr Ther Res Clin Exp. 58:1997;403-416.
38. Mantzoros C.S., Dunaif A., Flier J.S. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;1687-1691.
39. Mimura K., Umeda F., Hiramatsu S., et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diab Med. 11:1994;685-691.
40. Nagasaka S., Iwamoto Y., Ishikawa S., Kuzuya T., Saito T. Efficacy of troglitazone measured by insulin resistance index. Lancet. 350:1997;184.
41. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1994;1188-1193.
42. Ogihara T., Rakugi H., Ikegami H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 8:1995;316-320.
43. Onuma T., Tsutui M., Goto T., Boku A., Takebe T. The effect of a new oral hypoglycaemic drug, CS-045, on glucose tolerance and serum lipids in nonobese Japanese patients with non-insulin-dependent diabetes mellitus: a pilot study. Curr Ther Res. 55:1994;416-421.
44. Schwartz S., Raskin P., Fonseca V., Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 338:1998;861-866.
45. Sironi A.M., Vichi S., Gastaldelli A., et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther. 62:1997;194-202.
46. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diab Care. 15:1992;193-203.
47. Valiquett T., Balagtas C., Whitcomb R. Troglitazone dose-response study in patients with NIDDM [abstract no. 406]. Diabetes. 44:(Suppl. 1):1995;109A.
48. Nolan J.J., Olefsky J.M., Nyce M.R., Considine R.V., Caro J.F. Effect of troglitazone on leptin production. Studies in vitro and in human objects. Diabetes. 45:1996;1276-1278.
49. Anonymous. Rezulin labeling updated to recommend more frequent patient monitoring. J Am Med Assoc 1998;279:9.
50. Rezulin (troglitazone) - important drug warning. MedWatch news; www.fda.gov/medwatch/safety/1997/rezuli.htm.
51. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med. 338:1998;916-917.
52. Tanouye E. Diabetes drug spurs worries about safety. Wall Street Journal (Midwest ed.). 100:(108):1997;B1-B6.
53. Anonymous. Troglitazon: vervolg. Pharm Weekbl 1998;133:92.
54. Gaster B., Hirsch I.B. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 158:1998;134-140.
55. Henry R.R. Effects of troglitazone on insulin sensitivity. Diab Med. 13:1996;S148-S150.
56. Takino H., Okuno S., Uotani S. Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diab Res Clin Pract. 24:1994;167-172.
57. Izumino K., Sakamaki H., Ishibashi M., et al. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab. 82:1997;2391-2395.